AbbVie is acquiring Gilgamesh Pharmaceuticals’ lead drug candidate bretisilocin, used to treat moderate to severe major depressive disorder, for up to $1.2 billion.
Bretisilocin is a psychedelic compound that targets the 5-HT2A receptor and releases serotonin, according to an Aug. 25 news release from AbbVie. It is meant to deliver antidepressant effects with a shorter psychoactive experience compared to other drugs in its class, according to an AbbVie news release.
In a phase 2 trial, a single 10-milligram dose of the drug reduced depressive symptoms by 21.6 points on the Montgomery-Asberg depression rating scale, compared to a 12.1-point reduction for a low-dose comparison.
As part of the deal, Gilgamesh will spin off its remaining programs and staff into a new company that will continue its existing partnership with AbbVie, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.